Befotertinib
- Generic Name
- Befotertinib
- Indication
用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的治疗。
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 78
- Registration Number
- NCT06863506
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Hangzhou, Zhejiang, China
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- EGFRNon-Small Cell Lung CancerLocally Advanced Non-Small Cell Lung CancerPemetrexedCarboplatinBevacizumabAntineoplastic AgentsTyrosine Kinase Inhibitor
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Peng Zhang
- Target Recruit Count
- 60
- Registration Number
- NCT06755684
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 592
- Registration Number
- NCT06561620
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
Phase 2
Recruiting
- Conditions
- EGFR S768IEGFR G719XNon-small Cell Lung Cancer MetastaticEGFR L861Q
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 23
- Registration Number
- NCT06517953
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Phase 3
Recruiting
- Conditions
- Non-Small Cell Lung CancerEGFR Sensitive MutationAdjuvant Therapy
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 570
- Registration Number
- NCT06041776
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, China
🇨🇳Shanghai chest hospital, Shanghai, China
🇨🇳Peking University International Hospital, Beijing, China
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
Phase 2
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05007938
- Locations
- 🇨🇳
Feng Ye, Xiamen, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath